title: Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
authors.forename: Elisa
authors.initials: E
authors.lastname: Giovannetti
authors.forename: Carmelo
authors.initials: C
authors.lastname: Tibaldi
authors.forename: Alfredo
authors.initials: A
authors.lastname: Falcone
authors.forename: Romano
authors.initials: R
authors.lastname: Danesi
authors.forename: Godefridus J
authors.initials: GJ
authors.lastname: Peters
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000378:metabolism; D003564:Cytidine Deaminase / Q000097:blood / Q000235:genetics*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism; D005838:Genotype; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D018579:Patient Selection; D010641:Phenotype; D011110:Polymorphism, Genetic; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D003564:Cytidine Deaminase; D000093542:Gemcitabine